Viventia Bio Overview
- Year Founded
-
1995
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
4
Viventia Bio General Information
Description
Manufacturer of biopharmaceuticals based in Winnipeg, Canada. The company is engaged in the identification, development, production and marketing of biopharmaceuticals specializing in human monoclonal antibody therapies for the treatment of cancer.
Contact Information
Website
www.viventia.comCorporate Office
- 147 Hamelin Street
- Winnipeg, Manitoba R3T 3Z1
- Canada
Corporate Office
- 147 Hamelin Street
- Winnipeg, Manitoba R3T 3Z1
- Canada
Viventia Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Viventia Bio Comparisons
Industry
Financing
Details
Viventia Bio Competitors (99)
One of Viventia Bio’s 99 competitors is Immutep, a Corporation company based in Sydney, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immutep | Corporation | Sydney, Australia | ||||
| XBiotech | Corporation | Austin, TX | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Nektar Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Agios Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Viventia Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Viventia Bio Patents
Viventia Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10576163-B2 | Methods of treatment for epcam positive bladder cancer | Active | 12-Mar-2015 | ||
| EP-3268041-A1 | Dosing strategies for targeting epcam positive bladder cancer | Inactive | 12-Mar-2015 | ||
| EP-3268041-A4 | Dosing strategies for targeting epcam positive bladder cancer | Inactive | 12-Mar-2015 | ||
| AU-2016228760-B2 | Dosing strategies for targeting epcam positive bladder cancer | Inactive | 12-Mar-2015 | ||
| AU-2016228755-A1 | Methods of treatment for epcam positive bladder cancer | Active | 12-Mar-2015 | A61K47/6861 |
Viventia Bio Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Viventia Bio FAQs
-
When was Viventia Bio founded?
Viventia Bio was founded in 1995.
-
Where is Viventia Bio headquartered?
Viventia Bio is headquartered in Winnipeg, Canada.
-
What industry is Viventia Bio in?
Viventia Bio’s primary industry is Biotechnology.
-
Is Viventia Bio a private or public company?
Viventia Bio is a Private company.
-
What is the current valuation of Viventia Bio?
The current valuation of Viventia Bio is .
-
What is Viventia Bio’s current revenue?
The current revenue for Viventia Bio is .
-
Who are Viventia Bio’s investors?
Dan Family Holdings has invested in Viventia Bio.
-
Who are Viventia Bio’s competitors?
Immutep, XBiotech, Renova Therapeutics, Nektar Therapeutics, and Agios Pharmaceuticals are some of the 99 competitors of Viventia Bio.
-
When was Viventia Bio acquired?
Viventia Bio was acquired on 20-Sep-2016.
-
Who acquired Viventia Bio?
Viventia Bio was acquired by Sesen Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
